Saturday 17 October 2026 Export DHC’s income statement to Excel — free account

Diversified Healthcare Trust

DHC Real Estate Reit Healthcare Facilities

Diversified Healthcare Trust’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 2.84% from fiscal 2024. In the quarter to June 2026, revenue fell 4.53%, EPS grew 57.9%, free cash flow fell 94.0% and total debt fell 8.86%, each against the same quarter a year earlier. Dividend growth for three consecutive years, revenue growth for three; insiders bought in the last twelve months.

7.59 0.02 −0.26%

Follow DHC

Alert me

Market cap: $1.8B
P/E: 0.0×
Fwd P/E: 8.4×
Dividend yield: —
F-score: 5/9
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.10

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	1	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 9.72%

Capital & Financial Ratios $m

Market Cap 1,840.00

Revenue 1,500.13

Net Income (265.95)

Free Cash Flow 107.24

Net Debt 2,266.64

Current Ratio 4.67

Debt/Equity 1.52

P/E ratio 0.00

Fwd P/E 8.38

P/S ratio 1.22

P/B ratio 1.15

Past 5Y EPS Growth —

This Y EPS Growth 47.06%

Next Y EPS Growth 37.04%

Next Y revenue growth 295,171.14%

Next 5Y EPS Growth 29.33%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 57.28%

10-year low 10-year high

P/B against its own 10 years 73.72%

10-year low 10-year high

EV/Sales against its own 10 years 48.99%

10-year low 10-year high

EV/FCF against its own 10 years 76.17%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	0.03	0.01 0.01 0.01
2022	0.04	0.01 0.01 0.01 0.01
2021	0.04	0.01 0.01 0.01 0.01
2020	0.18	0.15 0.01 0.01 0.01
2019	0.81	0.38 0.15 0.15 0.15
2018	1.51	0.38 0.38 0.38 0.38
2017	1.51	0.38 0.38 0.38 0.38
2016	1.51	0.38 0.38 0.38 0.38

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	247	150	122	136
Receivables	6	4	4	—
Inventory	—	—	—	—
Other	—	—	—	—
	253	154	126	136

	2023	2024	2025	Q'26
Payables	7	9	23	—
ST’ Debt	—	—	—	—
Other	—	—	—	—
	30	32	53	29

Compound Annual Growth %

	10y	5y	3y
Sales	4.41%	(1.18%)	6.21%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(6.78%)	(8.66%)	(14.22%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	366	365	—	—	—
’25	387	383	389	380	1,538
’24	371	371	374	380	1,495
’23	346	346	357	362	1,410
’22	311	313	323	337	1,284
’21	363	346	337	337	1,383
’20	442	410	394	385	1,632

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	8	38	—	—	—
’25	(3)	53	(49)	(20)	(20)
’24	29	44	21	18	112
’23	6	26	(14)	(7)	10
’22	(7)	(25)	(5)	(3)	(40)
’21	35	(8)	(40)	(50)	(63)
’20	56	54	48	0	159

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(27)	21	—	—	—
’25	(43)	353	(75)	187	423
’24	(15)	7	(6)	(42)	(55)
’23	(51)	(22)	(74)	(59)	(206)
’22	581	(85)	(158)	(114)	224
’21	0	47	(83)	(152)	(188)
’20	30	73	14	1	118

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.18)	(0.16)	—	—	—
’25	(0.04)	(0.38)	(0.68)	(0.09)	(1.19)
’24	(0.36)	(0.41)	(0.41)	(0.36)	(1.55)
’23	(0.22)	(0.30)	(0.28)	(0.43)	(1.23)
’22	1.01	(0.46)	(0.34)	(0.27)	(0.07)
’21	(0.28)	(0.14)	(0.38)	1.54	0.73
’20	0.04	(0.11)	(0.45)	(0.07)	(0.59)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	13.53	18.26	11.13	7.05	2.00	2.35	0.61	0.64	2.13	2.00	Analyst estimates 2026–2028 Powerpack
	High	23.85	22.52	19.39	14.31	8.93	5.58	3.45	3.96	4.24	5.16
People
People	Employees	450	550	600	600	600	—	—	—	—	—
	Revenue/emp, $m	2.35	1.95	1.86	1.73	2.72	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	1,058	1,075	1,117	1,040	1,632	1,383	1,284	1,410	1,495	1,538
	Gross margin, %	62.21	61.53	59.58	52.98	24.24	21.07	13.59	16.75	17.31	18.11
	EBT	142	152	292	(83)	(133)	181	(21)	(273)	(371)	(321)
	EBT margin, %	13.38	14.11	26.17	(7.96)	(8.15)	13.11	(1.65)	(19.33)	(24.83)	(20.87)
	Net income	141	152	292	(83)	(134)	180	(16)	(294)	(370)	(286)
	Depreciation	289	277	287	288	271	277	248	296	389	340
Per share, $
Per share, $	Revenue	4.46	4.53	4.70	4.38	6.86	5.81	5.39	5.90	6.24	6.40
	Earnings	0.60	0.62	1.21	(0.37)	(0.59)	0.73	(0.07)	(1.23)	(1.55)	(1.19)
	Cash flow	1.79	1.77	1.65	1.12	0.67	(0.27)	(0.17)	0.04	0.47	(0.08)
	Capex	(1.23)	(0.93)	0.42	(0.08)	(0.17)	(0.52)	1.11	(0.91)	(0.70)	1.84
	Free cash flow	0.55	0.83	2.07	1.04	0.50	(0.79)	0.94	(0.86)	(0.23)	1.76
	Book value	13.48	13.80	13.39	12.11	11.02	11.19	11.07	9.78	8.18	6.93
	Shares, m	237	237	238	238	238	238	238	239	240	240
Valuation, ×
Valuation, ×	P/E	31.77	31.03	9.77	0.00	0.00	4.18	0.00	0.00	0.00	0.00
	P/S	4.28	4.25	2.49	1.93	0.60	0.53	0.12	0.61	0.37	0.76
	P/B	1.41	1.39	0.88	0.70	0.37	0.28	0.06	0.37	0.28	0.70
	EV/Sales	7.75	7.63	5.69	5.68	2.87	2.45	1.96	2.75	2.52	2.53
	EV/FCF	62.32	41.42	12.93	23.92	39.81	(18.09)	11.21	(18.81)	(68.01)	9.21
Cash, $m
Cash, $m	Operating cash flow	424	419	393	266	159	(63)	(40)	10	112	(20)
	Capex	(293)	(221)	99	(19)	(41)	(124)	265	(217)	(168)	442
	Free cash flow	132	198	492	247	118	(188)	224	(206)	(55)	423
Balance, $m
Balance, $m	Working capital	13	(19)	8	21	43	179	(38)	223	122	72
	Total debt	3,735	3,675	4,094	3,956	3,802	3,677	3,048	2,817	2,911	2,401
	Net debt	3,700	3,627	4,024	3,903	3,711	2,660	2,360	2,570	2,761	2,279
	Shareholders’ equity	3,199	3,277	3,180	2,877	2,619	2,662	2,639	2,337	1,959	1,666
Returns, %
Returns, %	ROA	1.96	2.03	3.97	(1.28)	(2.12)	2.66	(0.25)	(5.13)	(7.00)	(6.02)
	ROIC	2.75	2.49	1.97	0.89	(0.13)	(0.37)	(1.17)	(1.32)	(1.67)	(3.25)
	ROE	4.31	4.56	8.89	(2.91)	(5.07)	6.61	(0.60)	(11.80)	(17.24)	(15.78)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
HR Healthcare Realty Trust Incorporated	$6.0B	— (loss-making)	— (loss-making)	−5.26% (below 0%: shrinking)	n/m	−28.80% (below 0%: shrinking)	64.88%	13.83%	Compare
SBRA Sabra Healthcare REIT, Inc.	$4.9B	74.4×	27.3×	+24.70% (above 0%: growing)	n/m	−666.09% (below 0%: shrinking)	100.00%	(13.59%)	Compare
NHI National Health Investors, Inc.	$3.2B	19.1×	20.2×	+33.81% (above 0%: growing)	+45.57% (above 0%: growing)	+2,585.45% (above 0%: growing)	72.18%	41.09%	Compare
LTC LTC Properties, Inc.	$2.3B	15.9×	18.8×	+64.11% (above 0%: growing)	+72.73% (above 0%: growing)	−213.92% (below 0%: shrinking)	100.00%	31.24%	Compare
MPT Medical Properties Trust, Inc.	$1.9B	— (loss-making)	39.5×	+7.87% (above 0%: growing)	n/m	−15.15% (below 0%: shrinking)	95.68%	3.31%	Compare
DHC Diversified Healthcare Trust	$1.8B	— (loss-making)	8.4×	−4.53% (below 0%: shrinking)	n/m	−93.96% (below 0%: shrinking)	23.11%	(0.14%)
STRW Strawberry Fields REIT, Inc.	$725.3M	19.7×	19.3×	+5.78% (above 0%: growing)	0.00%	+55.53% (above 0%: growing)	89.67%	53.67%	Compare
UHT Universal Health Realty Income Trust	$530.8M	27.4×	31.2×	+0.49% (above 0%: growing)	+30.30% (above 0%: growing)	−69.28% (below 0%: shrinking)	94.29%	36.83%	Compare
XRN Chiron Real Estate Inc.	$454.1M	8.1×	— (loss-making)	+4.68% (above 0%: growing)	n/m	−18.02% (below 0%: shrinking)	100.00%	23.19%	Compare
Median of peers	$2.1B	19.4×	23.8×	+6.83%	+37.93%	−23.41%	94.99%	27.22%

All 16 Reit Healthcare Facilities stocks →

Diversified Healthcare Trust (DHC) key facts

Concern: Diversified Healthcare Trust reported a net loss of $285.9 million, or a loss of $1.19 per share, for fiscal 2025.
Strength: Diversified Healthcare Trust’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 2.84% from fiscal 2024.
Diversified Healthcare Trust (DHC) is a Reit Healthcare Facilities company in the Real Estate sector, listed on Nasdaq.
As of October 16, 2026, DHC traded at $7.59, a market capitalization of $1.8 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 1.2× sales.
Return on equity was −15.8% and debt-to-equity 1.52.
Its Piotroski F-score is 5 out of 9 for fiscal 2025.